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The ubiquitin-proteasome system is essential for
maintaining protein homeostasis. However, pro-
teasome dysregulation in chronic diseases is poorly
understood. Through genome-wide cell-based
screening using 5,500 cDNAs, a signaling pathway
leading to NFkB activation was selected as an
inhibitor of 26S proteasome. TNF-a increased S5b
(HGNC symbol PSMD5; hereafter S5b/PSMD5)
expression via NFkB, and the surplus S5b/PSMD5
directly inhibited 26S proteasome assembly and
activity. Downregulation of S5b/PSMD5 abolished
TNF-a-induced proteasome inhibition. TNF-a
enhanced the interaction of S5b/PSMD5 with S7/
PSMC2 in nonproteasome complexes, and inter-
ference of this interaction rescued TNF-a-induced
proteasome inhibition. Transgenic mice expressing
S5b/PSMD5 exhibited a reduced life span and pre-
mature onset of aging-related phenotypes, including
reduced proteasome activity in their tissues. Con-
versely, S5b/PSMD5 deficiency in Drosophila mela-
nogaster ameliorated the tau rough eye phenotype,
enhanced proteasome activity, and extended the
life span of tau flies. These results reveal the critical
role of S5b/PSMD5 in negative regulation of protea-
some by TNF-a/NFkB and provide insights into pro-
teasome inhibition in human disease.INTRODUCTION
The ubiquitin-proteasome system (UPS) is the major mechanism
for selective protein degradation in eukaryotic cells (Ciechan-
over, 2005). Most early studies of the UPS have focused on
selective degradation of cellular proteins following their ubiquiti-
nation by E1, E2, and E3; less is known about the direct regula-
tion of proteasome activity. A few studies have shown that
proteasome expression and function can be regulated in a
tissue-specific or signal-dependent manner (Gaczynska et al.,
1993; Murata et al., 2007). In cells exposed to interferon-g or viral
infection, for example, immunoproteasome is induced to stimu-
late production of antigenic peptides (Gaczynska et al., 1993).CelThe thymus produces a thymus-specific proteasome subunit
to enhance the tissue-specific function of proteasome (Murata
et al., 2007). In addition, TCF11 (long isoform of Nrf1) was iden-
tified as themajor transcription factor responsible for the expres-
sion of proteasome subunits during proteasome inhibition
(Radhakrishnan et al., 2010; Steffen et al., 2010).
Altered UPS function is associated with chronic neurodegen-
erative diseases, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), and amyotrophic lateral
sclerosis (ALS), which exhibit reduced activity of the degradation
system and accumulation of ubiquitin conjugates and aggrega-
tion-prone proteins (Ciechanover and Brundin, 2003; Gao and
Hong, 2008). Indeed, E2-25K/Hip-2, an E2 enzyme that inhibits
proteasome activity, is upregulated in the brains of TG2576
mice and patients with AD (Song et al., 2003, 2008). Accumula-
tion of hyperphosphorylated and aggregated tau, a hallmark of
tauopathy, including AD, is also contributed by reduced activity
of the degradation system in the brain, leading to neuronal
degeneration (Ballatore et al., 2007; Dickey et al., 2006; Gold-
baum et al., 2003; Shimura et al., 2004). In these diseases the
reduced activity and malfunction of proteasome likely leads to
the accumulation of toxic proteins, which may be the key risk
factor(s) responsible for neurodegeneration (Bence et al., 2001;
Berke and Paulson, 2003). However, cellular signal(s) andmolec-
ular determinant(s) responsible for the regulation of proteasome
activity remain unknown.
Inflammation often contributes to the development of many
diseases. Particularly, levels of inflammatory mediators, such
as tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b),
are elevated in neurodegenerative diseases, including AD
(Campbell, 2004). TNF-a contributes to Ab-induced impairment
of learning/memory; cytokine inhibition suppresses Ab-induced
neurotoxicity and reduces tau phosphorylation (Medeiros et al.,
2007; Shi et al., 2011; Wang et al., 2005). Moreover, anti-
TNF-a antibody treatment produces positive effects in animal
models of neuronal diseases (Tweedie et al., 2007). In addition,
lipopolysaccharide (LPS)-induced inflammation exacerbates
the symptoms of these diseases in mouse models (Gao et al.,
2003; Gao and Hong, 2008). Despite the proposed contribution
of inflammation to neurodegeneration in vitro and in vivo, little
is known about themolecular mechanism bywhich inflammatory
mediators regulate neuropathology via the UPS.
In the present study we identified the TNF-a/NFkB inflamma-
tory signal as an important regulator of proteasome activity.
We show that TNF-a/NFkB inhibits 26S proteasome assemblyl Reports 2, 603–615, September 27, 2012 ª2012 The Authors 603
and thus reduces proteasome activity via abnormal expression
of S5b (HGNC symbol PSMD5; hereafter S5b/PSMD5), which
contributes to UPS-associated neuronal disease and tau
pathology.
RESULTS
Functional Identification of the NFkB Pathway
in Proteasome Regulation
To uncover signals and regulators that directly modulate protea-
some activity, we established a cell-based assay using degron
(CL1), which is rapidly degraded by 26S proteasome in cells
(Gilon et al., 1998). By cotransfecting HEK293T cells grown on
96-well culture plates with green fluorescent protein tagged
with CL1 (GFPu) and various genes of interest, we screened
5,500 full-length cDNAs for their stimulatory effects on GFPu
fluorescence. The 5,500 cDNAs encode protein kinases,
membrane proteins, and other proteins that are expressed in
the brain and are associated with human diseases. Using this
gain-of-functional screening method, we isolated putative posi-
tive cDNA clones that affected GFPu fluorescence (i.e., protea-
some activity).
Of the 5,500 cDNAs, 68 genes increased the fluorescence and
accumulation of GFPu by more than 2-fold, compared to control
(data not shown). The 68 genes encode protein kinases (29%),
proteins with unknown functions (22%), proteins functioning in
NFkB activation (16%), and others (Figure 1A). Surprisingly,
11 genes encode signal mediators and protein kinases that
function in the signaling pathway leading to NFkB activation
(Ghosh and Karin, 2002), including TAK1, NIK, CHUK, IKKε,
TRAF2, MAP3K11, T2BP, MEKK1, MAPK9, MAP2K1IP1, and
MKK7. Using western blot analyses, we confirmed that ectopic
expression of these clones increased GFPu accumulation but
had no effect on GFP (Figure 1B), suggesting that a signaling
pathway leading to NFkB activation may inhibit proteasome
activity.
TNF-a Increases S5b/PSMD5 Expression to Inhibit
Proteasome Activity via NFkB
Given that the inflammatory signal triggered by TNF-a activates
NFkB via TAK1, NIK, and CHUK, we examined the effect of
TNF-a on proteasome activity. Treatment of TNF-a elicited an
accumulation of GFPu and ubiquitin conjugates (Figure 1C). In
enzyme assays using fluorogenic substrates, TNF-a suppressed
the chymotrypsin-, trypsin-, and caspase-like activities of pro-
teasome to 70% of control levels at 6 hr (Figure 1D), paralleling
the accumulation patterns of GFPu and ubiquitin conjugates
(Figure 1C). We next investigated the roles of various kinase
clones in the TNF-a-induced inhibition of proteasome activity.
Stable expression of an IkBa or CHUK dominant-negative
mutant abolished TNF-a-induced GFPu accumulation (Fig-
ures 1E and 1F). In addition, reduced expression of MEKK1,
TAK1, NIK, CHUK, IKKb, or IKKε by shRNAs weakened the
TNF-a-induced GFPu accumulation (Figure 1G). TNF-a thus
appears to inhibit proteasome activity via the aforementioned
kinases. In addition, proteasome activity was suppressed by
IL-1b and LPS, both of which are known to activate NFkB
(data not shown).604 Cell Reports 2, 603–615, September 27, 2012 ª2012 The AuthorBecause NFkB is a transcription factor, we hypothesized
that the expression of cellular factor(s), including protea-
some subunits, may be regulated by NFkB to modulate protea-
some activity. We therefore collected 29 cDNAs encoding pro-
teasome subunits and their associated factors, and tested their
effects on GFPu accumulation (Table S1). Expressional analyses
revealed that ectopic expression of S1/PSMD1, S4/PSMC1, S7/
PSMC2, or S5b/PSMD5 significantly induced GFPu accumula-
tion. Of these proteasome subunits and factors, only S5b/
PSMD5 mRNA and protein levels increased at 6 hr after treat-
ment with TNF-a and returned to control levels at 24 hr (Figures
2A and 2B). Like other assembly factors, immunoproteasome
subunits were not induced by TNF-a (Figures S1A and S1B)
(Hallermalm et al., 2001). In addition the expression of TCF11/
Nrf1, which was identified as a transcriptional factor for protea-
some gene expression, was not regulated by TNF-a and did
not affect S5b/PSMD5 expression (Figures 2B and S1C).
Unlike in HEK293T cells, in primary cultured cortical and
hippocampal neurons exposed to TNF-a, S5b/PSMD5 protein
began to accumulate at 6 hr and remained high until 24 hr (Fig-
ure 2C). In neurons the kinetics of proteasome activity inhibition
was similar to that of S5b/PSMD5 induction. Likewise, incuba-
tion of mouse embryo fibroblasts (MEFs) with TNF-a increased
S5b/PSMD5 protein level and suppressed proteasome activity.
However, TNF-a failed to induce S5b/PSMD5 expression and
did not inhibit proteasome activity in NFkB p50/ and p65/
MEFs (Figure 2D). Furthermore, ectopic expression of p65 or
p50 increased S5b/PSMD5 level and inhibited proteasome
activity (Figure 2E). Together, these results suggest that TNF-a
increases S5b/PSMD5 expression and inhibits proteasome
activity via NFkB.
To assess the role of S5b/PSMD5 in TNF-a-induced inhibition
of proteasome activity, we targeted the expression of S5b/
PSMD5 using five different shRNAs and two siRNAs (Figures
S2A and S2B). Downregulation of S5b/PSMD5 expression
enhanced proteasome activity and abolished TNF-a-induced
GFPu accumulation and proteasome inhibition (Figures 3A, 3B,
and S2A–S2C). Consistently, ectopic expression of S5b/
PSMD5 reduced proteasome activity and increased the fluores-
cence of GFPu as well as that of another short-lived GFPUbG76V-
GFP (Dantuma et al., 2000) (Figures 3B and S3A–S3D). Also,
S5b/PSMD5 overexpression rescued the S5b/PSMD5 knock-
down effect on GFPu accumulation (Figure S2D). In addition,
proteasome activity was further inhibited by the increasing
concentrations of MG132, a potent inhibitor of proteasome, in
S5b/PSMD5-overexpressing cells (Figure S3E). We confirmed
that S5b/PSMD5 regulated GFPu accumulation by affecting
protein degradation but not transcription (Figures S3F and
S3G). Interestingly, incubation of cell extracts with purified
S5b/PSMD5 protein caused both accumulation of ubiquitin
conjugates and inhibition of proteasome activity (Figures 3C
and 3D), indicating that S5b/PSMD5 plays an essential role in
the proteasome inhibition. These findings support our hypoth-
esis that surplus S5b/PSMD5 functions as a negative regulator
of proteasome activity. Unlike S5b/PSMD5, expression or
knockdown of other 19S proteasome assembly factors, such
as p27/PSMD9 and p28/PSMD10, did not significantly affect
proteasome activity (Figure 3E).s
Figure 1. Identification of the TNF-a/NFkB Signaling Pathway as a Proteasome Inhibitory Pathway by Gain-of-Functional Screening
(A) Classification of the 68 putative positive clones based on their cellular functions.
(B) HEK293T cells were cotransfected for 36 hr withGFPu and pcDNA (Con) or the indicated clones. Cell extracts were prepared and analyzed bywestern blotting.
A control plasmid encoding EGFP (GFP) was included in every transfection.
(C) HEK293T cells were transfected with GFPu for 24 hr and then left untreated or treated with TNF-a (50 ng/ml) for the indicated times or with MG132 (MG, 1 mM)
for 12 hr. Cell extracts were then analyzed by western blotting.
(D) HEK293T cells were treated with TNF-a or MG132 as in (C). Cell extracts were prepared as described in Extended Experimental Procedures, and three types
of proteasome activities were measured using Suc-LLVY-AMC (white box), Bz-VGR-AMC (gray box), and Ac-GPLD-AMC (black box). Error bars represent
mean ± SD from at least three independent experiments. *p < 0.001.
(E and F) HEK293T cells stably expressing pcDNA3, IkBa-DN (#1 and #5) (E), or CHUK-DN (#3 and #5) (F) were transfected with GFPu for 36 hr and then treated
with TNF-a for the indicated times. Western blot analyses were performed.
(G) HEK293T cells were cotransfected for 42 hr with GFPu and shRNAs targeted to MEKK1, TAK1, NIK, CHUK, IKKb, or IKKε and exposed to TNF-a for the
indicated times. GFPu levels in the cell extracts were examined by western blot analysis as in (E).
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Figure 2. Increased S5b/PSMD5 Expression and Proteasome Inhibition by TNF-a/NFkB
(A and B) HEK293T cells were treated with TNF-a (50 ng/ml) for the indicated times, and total RNA and proteins were isolated and analyzed by RT-PCR (A) and
western blotting (B), respectively. See also Figure S1 and Table S1.
(C) Cells were treated with TNF-a (50 ng/ml) for the indicated times, and cell extracts of primary rat cortical (left) and hippocampal neurons (right) were examined
for proteasome activity (top) and analyzed by western blotting (bottom). Error bars represent mean ± SD. *p < 0.01, **p < 0.0001.
(D) WT, NFkB p50/, and NFkB p65/ MEFs were treated with TNF-a (50 ng/ml) for the indicated times, after which cell extracts were prepared for
measurement of chymotrypsin-like activity using Suc-LLVY-AMC (top) and for western blot analyses (bottom). Error bars represent mean ± SD (n = 3). *p < 0.005.
KO, knockout.
(E) HEK293T cells were transfected for 36 hr with pcDNA (Con), NFkB p50, p65, or p50+p65 subunits, after which chymotrypsin-like activity was measured in cell
extracts using Suc-LLVY-AMC (top). S5b/PSMD5 expression was assessed by western blotting (bottom). Error bars represent mean ± SD. *p < 0.001.Surplus S5b/PSMD5 Inhibits 26S Proteasome Assembly
Next, to determine themechanism bywhich S5b/PSMD5 inhibits
proteasome activity, we performed in vitro enzyme assays and
native gel analyses using purified 26S proteasome. Addition of
purified S5b/PSMD5 protein apparently reduced the purified
26S proteasome activity in a dose-dependent manner, whereas
the S5b/PSMD5 RE mutant protein that is defective in S7/
PSMDC2 binding (Le Tallec et al., 2009) did not exhibit an inhib-
itory effect (Figure 4A, left and middle; Figure S4A). On the other
hand, addition of other 19S proteasome assembly factors,
including p27/PSMD9 and p28/PSMD10, did not inhibit the
purified 26S proteasome activity (Figure S4B). In native gel anal-606 Cell Reports 2, 603–615, September 27, 2012 ª2012 The Authoryses, addition of S5b/PSMD5 protein appeared to inhibit the
assembly and activity of 26S proteasome (RP2-CP and RP-CP)
and increased the activity of 20S proteasome and the amounts
of 20S core particle (CP) and S5a/PSMD4 (regulatory particle
[RP]) (Figure 4A, right). On the other hand, the purified S5b/
PSMD5R184Emutant protein did not exhibit any inhibitory effect
on the assembly and activity of 26S proteasome (Figure 4A,
right). Thus, it appears that excess S5b/PSMD5 directly inhibits
the assembly and activity of 26S proteasome in vitro.
We further performed gel filtration (FPLC) analysis using
Superose 6 and examined cellular proteasome assembly in
detail. TNF-a treatment shifted the 19S and 20S core subunitss
Figure 3. Inhibition of Proteasome Activity
by TNF-a via S5b/PSMD5
(A and B) HEK293T cells were cotransfected for
42 hr with GFPu and pcDNA, S5b/PSMD5 cDNA,
or S5b/PSMD5 shRNA#2, after which they were
left untreated or incubated with TNF-a (50 ng/ml)
for 6 hr. Cell extracts were analyzed by western
blotting (A). The arrowhead indicates a nonspecific
signal. Fluorogenic substrates were used to
measure three types of proteasome activities in
the same cell extracts (B). Error bars represent
mean ± SD (n = 3) *p < 0.05, **p < 0.0001. See also
Figures S2 and S3.
(C and D) HEK293T cell lysates (100 mg) were
incubated with purified His-S5b/PSMD5 protein
(3 mg) for the indicated times. Western blot anal-
yses were then performed (C), and proteasome
activities were examined using Suc-LLVY-AMC
(D). Error bars represent mean ± SD (n = 3).
*p < 0.01.
(E) HEK293T cells were transfected for 48 hr
with S5b/PSMD5, p27/PSMD9, p28/PSMD10,
and PAAF1 cDNAs (overexpression) or siRNAs
(knockdown), and cell lysates were examined for
proteasome activity using Suc-LLVY-AMC (left)
and analyzed by western blotting (right). Error bars
represent mean ± SD.(three fractions) toward low molecular weight fractions (Fig-
ure 4B, middle; Figure S4C). A similar shift was detected in cells
overexpressing S5b/PSMD5 (Figure 4B, bottom; Figure S4C).
Enzyme assays of each fraction showed that the activities in
26S proteasome fractions were significantly suppressed by
TNF-a and more markedly inhibited in cells overexpressing
S5b/PSMD5. In contrast, enzymatic activities in the 20S protea-
some fractions were increased by TNF-a or S5b/PSMD5 overex-
pression in the presence of SDS (Figures 4C andS4E).Moreover,
immunoprecipitation assays revealed that the interactions of
20S core subunits with the 19S subunits were inhibited by
TNF-a and S5b/PSMD5 overexpression, but not by S5b/
PSMD5 R184E overexpression (Figure 4D). Taken together,
these results suggest that TNF-a and S5b/PSMD5 overexpres-
sion suppress the assembly of 26S proteasome.Cell Reports 2, 603–615, SeInteraction of Excess S5b/PSMD5
with S7/PSMC2 Is Critical for
Proteasome Inhibition
S5b/PSMD5 is known to interact with
S4/PSMC1, S7/PSMC2, and S2/PSMD2
in vitro (Gorbea et al., 2000). We also
found that S5b/PSMD5 interacted with
S7/PSMC2 in the brain tissue of S5b/
PSMD5 transgenic (Tg) mice (Figure
S5A). Interestingly, in cells overexpress-
ing HA-S5b/PSMD5 and His-S7/PSMC2,
TNF-a enhanced the interaction of HA-
S5b/PSMD5 with S7/PSMC2 without
affecting the total cellular levels of S7/
PSMC2 (Figure 5A, top). On the other
hand, TNF-a had no effect on the interac-tion of S5b/PSMD5 with either S4/PSMC1 or S2/PSMD2, and
S5b/PSMD5 did not interact with S5a/PSMD4 (Figure 5A, middle
and bottom; Figure S5B), indicating that TNF-a enhances the
interaction of S5b/PSMD5with S7/PSMC2.We further examined
the interaction of endogenous S5b/PSMD5 with S7/PSMC2 in
the proteasome and nonproteasome fractions obtained from
gel filtration (FPLC) analysis. Unlike the other 19S subunits,
which were detected in the proteasome fractions (12–24) from
FPLC analysis, the majority of S5b/PSMD5 was detected in the
nonproteasome fractions (33–46) of control cells (Figures 4B
and 5B, top; Figure S4D). Consistently, TNF-a significantly
increased the amounts of S7/PSMC2 and S5b/PSMD5 in the
nonproteasome fractions (Figure 5B, middle). We therefore
pooled the nonproteasome fractions (30–45) and performed
immunoprecipitation analyses. Compared to control, TNF-aptember 27, 2012 ª2012 The Authors 607
Figure 4. TNF-a and Excess S5b/PSMD5 Inhibit 26S Proteasome Assembly and Activity
(A) Purified 26S proteasome (3 mg) was incubated with His-S5b/PSMD5 (WT) or His-S5b/PSMD5R184E (RE) protein (5 mg) for 3 hr, and the reactionmixtures were
subjected to proteasome activity analysis using Suc-LLVY-AMC (left) and pull-down analyses with Ni-NTA resin and western blotting (middle). The samples were
also resolved on native gel (right), and the gel was then overlaid with Suc-LLVY-AMC (Native gel, left) before transfer to a nitrocellulose membrane for western
blotting (Native gel, middle and right). The RP and catalytic particle (CP) of proteasome complexes are shown. Error bars represent mean ± SD. *p < 0.0001.
(B and C) HEK293T cells were exposed to TNF-a (50 ng/ml) for 6 hr or transfected with S5b/PSMD5 for 36 hr. Cell extracts were fractionated by gel filtration using
a Superose 6 column, and the respective locations of 26S and 20S in the fractions are indicated by arrows. Sets of three fractions were analyzed by western
blotting using the indicated antibodies against proteasome subunits (B). Blue dextran (2,000 kDa), thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa),
and aldolase (158 kDa) were used asmolecular weight markers. Chymotrypsin-like proteasome activity wasmeasured in each fraction using Suc-LLVY-AMC (C).
Fr. No., fraction number. See also Figure S4.
(D) HEK293T cells were transfected with pcDNA, S5b/PSMD5WT, or S5b/PSMD5 R184E for 36 hr or treated with TNF-a for 6 hr. Cell extracts were prepared and
subjected to immunoprecipitation (IP) analyses using preimmune serum (Pre) or anti-20S core antibody (20S). Whole-cell lysates (Input) and the immunopre-
cipitates were analyzed by western blotting.
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Figure 5. TNF-a Enhances the Interaction between S5b/PSMD5 and S7/PSMC2 in Nonproteasome Complexes
(A) HEK293T cells were cotransfected for 36 hr with HA-S5b/PSMD5 and His-S7/PSMC2, S4/PSMC1, or S5a/PSMD4, and then left untreated or treated with
TNF-a (50 ng/ml) for 6 hr. Following immunoprecipitation (IP) using anti-HA antibody, western blot analyses were performed. See also Figure S5.
(B) The nonproteasome fractions (33–46) in Figure 4B were analyzed by western blotting.
(C) Fractions 30–45 of Mock (lane C) or TNF-a-treated cell lysates (lane T) in (B) were pooled (Total) and subjected to IP assays using preimmune serum (Pre),
anti-S5b/PSMD5, or anti-S7/PSMC2 antibody. Western blot analyses were then performed.enhanced the interaction between S5b/PSMD5 and S7/PSMC2
in the nonproteasome fractions (Figure 5C).
To identify the S5b/PSMD5 domain that interacts with S7/
PSMC2 and inhibits proteasome activity, we constructed serial
deletion mutants based on the predicted secondary structure
of S5b/PSMD5 (Figure 6A). Immunoprecipitation analyses re-
vealed that the S5b/PSMD5 N3 mutant interacted with both
His-S7/PSMC2 and endogenous S7/PSMC2, whereas the other
S5b/PSMD5mutants failed to do so (Figure 6B). Among the S5b/
PSMD5mutants, only the S5b/PSMD5 N3mutant induced GFPu
accumulation (Figure 6C). The observations suggest that the
interaction between S5b/PSMD5 and S7/PSMC2may be critical
for the inhibition of proteasome activity.CelWe then explored the contribution of the S5b/PSMD5-S7/
PSMC2 interaction to proteasome inhibition. We then synthe-
sized Tat-tagged S5b/PSMD5 peptide (amino acid residues
181–188) to target the interaction between S5b/PSMD5 and
S7/PSMC2 (Figure 6A). When added to cells, the Tat-S5b
(181–188) peptide rescued TNF-a-induced GFPu accumulation
in a dose-dependent manner (Figure 6E, left; Figure 6F) and
inhibited the interaction between S5b/PSMD5 and S7/PSMC2
in cells (Figure 6E, right). In contrast the Tat-S5b (181–188)
R184E peptide failed to exhibit these activities. Collectively,
these observations strongly suggest that the interaction between
S5b/PSMD5 and S7/PSMC2 is critical for TNF-a-induced inhibi-
tion of proteasome activity.l Reports 2, 603–615, September 27, 2012 ª2012 The Authors 609
Figure 6. The Interaction between S5b/PSMD5 and S7/PSMC2 Is Critical for Proteasome Inhibition
(A) Schematic diagram of S5b/PSMD5 mutants and Tat-S5b peptides (left) and summary of their abilities to interact with S7/PSMC2 and modulate degron
accumulation (right). The numbers indicate amino acid residues (AA) of human S5b/PSMD5.
(B) HEK293T cells were cotransfected with S5b/PSMD5 deletion mutants and His-S7/PSMD5, and immunoprecipitation (IP) assays were performed with anti-HA
antibody. Total cell lysates (Input) (left) and the immunoprecipitates (IP) (right) were analyzed by western blotting.
(C) HEK293T cells were cotransfected with S5b/PSMD5 deletion mutants and GFPu for 36 hr and cell extracts analyzed by western blotting.
(D) HEK293T cells were transfected with pcDNA, HA-S5b/PSMD5 (WT), or HA-S5b/PSMD5 R184E (RE) for 36 hr and left untreated or treated with TNF-a for 6 hr,
after which cell lysates were subjected to an IP assay to examine the interaction with endogenous S7/PSMC2. Western blot analyses were performed.
(E) HEK293T cells were transfected with GFPu for 24 hr, left untreated or pretreated with 10 mMTat-S5b (181–188) (WT) or Tat-S5b (181–188) R184E (RE) peptide
for 18 hr, and then exposed to TNF-a (50 ng/ml) for 6 hr. Cell extracts were prepared and analyzed by western blotting (left). After transfection with HA-S5b/
PSMD5 for 24 hr, HEK293T cells were incubated with 50 mM Tat-S5b (181–188) (WT) or Tat-S5b (181–188) RE peptide for an additional 24 hr. Cell extracts were
immunoprecipitated using anti-HA antibody (right).
(F) HEK293T cells were transfected with GFPu for 24 hr and then incubated with the indicated concentrations of Tat-S5bWT peptide. Western blot analyses were
performed (left), and proteasome activities were measured (right). Error bars represent mean ± SD (n = 3). *p < 0.001.
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Figure 7. Expression Level of S5b/PSMD5
Regulates Proteasome Activity and Tauop-
athy in Animal Models
(A) Mouse tissues were collected from 4-week-old
WT and S5b/PSMD5 Tg mice (lines 147, 148,
and 9), and tissue extracts were analyzed for
proteasome activities using Suc-LLVY-AMC. Pro-
teasome activity inWT tissuewas assigned a value
of 100, and activity in the S5b/PSMD5 Tg tissue is
expressed relative to that of the WT. F, female; M,
male. Error bars represent mean ± SD (n = 3).
(B) Cortical tissues were collected from 3-, 6-, 9-,
and 12-month-old S5b/PSMD5 Tg mice and their
littermates, tissue extracts were analyzed by
western blotting (top), and proteasome activity
was measured using Suc-LLVY-AMC (bottom).
Error bars represent mean ± SD. **p < 0.0001. See
also Figure S6.
(C) Life span of WT (n = 30) and S5b/PSMD5 Tg
(n = 54) mice.
(D) WT (1, w1118) and S5b/PSMD5 mutant (2,
CG12906f05782; 3, CG12906EY23373) flies were
crossed to generate tau rough eye/WT (4, gl-tau2.1
X w1118), tau rough eye/S5b/PSMD5 heterozygote
(5, gl-tau2.1 X CG12906f05782), and tau rough
eye/S5b/PSMD5 heterozygote (6, gl-tau2.1 X
CG12906EY23373) lines. Typical fly eyes are shown.
(E) Fly heads were collected, and tissue extracts
were analyzed for proteasome activities (top).
Error bars represent mean ± SD. Total RNA was
isolated and analyzed by RT-PCR (bottom). The fly
genotypes are (1) w1118, (2) w1118CG12906f05782,
(3) y1w67c23CG12906EY23373, (4) w1118; gl-tau2.1/+,
(5) w1118CG12906f05782/+; gl-tau2.1/+, and (6)
y1w67c23CG12906EY23373/+; gl-tau2.1/+. *p < 0.001.
(F) Newly eclosed adults were collected, and
more than 200 flies were placed in each culture
vial. Flies were maintained at 25C and moved to a
humidified temperature-controlled environmental
chamber at 29C for life span measurement.
Every 2 days, flies were transferred to new
vials, and the dead flies were enumerated. The
fly genotypes are w1118, w1118CG12906f05782,
y1w67c23CG12906EY23373, w1118 elav-gal4; UAS-
tauR406W/+, w1118CG12906f05782/w1118 elav-gal4;
UAS-tauR406W/+, and y1w67c23CG12906EY23373/
w1118elav-gal4; UAS-tauR406W/+.
(G) Proposed model for the role of S5b/PSMD5 in
TNF-a/NFkB-mediated proteasome inhibition and
tauopathy pathogenesis. S5b/PSMD5 protein
expression is induced by TNF-a/NFkB and inter-
feres with the assembly and, thus, activity of 26S
proteasome via its increased interaction with S7/
PSMC2, leading to accumulation of ubiquitin
conjugates and p-Tau in the affected neurons for
neurodegeneration. See also Figure S7.Proteasome Regulation by S5b/PSMD5 in Animal
Models and Its Contribution to Tau Pathology
To assess the effect of S5b/PSMD5 upregulation on pro-
teasome activity in vivo, we generated S5b/PSMD5 Tg mice
using the CMV/b-actin promoter (pCAGGS), which drives the
ubiquitous expression of HA-S5b/PSMD5 (Niwa et al., 1991).
HA-S5b/PSMD5 was expressed in the brain and almost allCelother tissues of 4-week-old S5b/PSMD5 Tg mice (line 147)
(Figure 7B, top; Figure S6A). In enzyme assays, proteasome
activities were downregulated by 30%–40% in most of the
tissues of all mouse lines (147, 148, and 9) examined (Fig-
ures 7A and S6B). Particularly, compared to age-matched
littermates, accumulation of ubiquitin conjugates was evident,
and proteasome activity was reduced by more than 30% inl Reports 2, 603–615, September 27, 2012 ª2012 The Authors 611
the cortex of 3- to 12-month-old S5b/PSMD5 Tg mice
(Figure 7B).
The S5b/PSMD5 Tg mice (line 147) were apparently smaller
than the age-matched littermates, and their body weights were
significantly decreased to 40% and 25% of control in 9-month-
old female and male mice, respectively (Figures S6C–S6E). In
addition, skeletal changes, such as curvature of the upper
back, and loss of hair glossiness were evident in 9-month-old
S5b/PSMD5 Tgmice (line 147) (Figure S6C). Furthermore, tumor
suppressor p53 was upregulated in the cortex of S5b/PSMD5 Tg
mice compared to the littermates (Figure 7B, top). S5b/PSMD5
Tg mice exhibited a shorter life span (average 343 days) than
the wild-type (WT) littermate (average 782 days), as evaluated
by a Kaplan-Meier survival curve (Figure 7C). These observa-
tions are consistent with earlier reports showing a strong associ-
ation of UPS inhibition and inflammation with the premature
aging phenotype (Hamer et al., 2010; Liu et al., 2011; Min
et al., 2008).
The CG12906 gene has been identified as a fly homolog of the
human S5b/PSMD5 gene (Le Tallec et al., 2009); therefore, we
measured proteasome activity in CG12906 mutant flies.
Although two lines of S5b/PSMD5 mutant flies (CG12906f05782
and CG12906EY23373) showed no significant morphological
defects in their eyes (Figure 7D, top), enzyme assays revealed
that the proteasome activity was significantly enhanced in
the S5b/PSMD5 mutant flies, particularly in the S5b/
PSMD5-deficient CG12906f05782 fly (Figure 7E, top). RT-PCR
analyses revealed that S5b/PSMD5 was not expressed in the
CG12906f05782 fly but was expressed to a small degree in the
CG12906EY23373 fly (Figure 7E, bottom), showing a correlation
between the expression level of S5b/PSMD5 and the protea-
some activity in these flies.
Tau, a microtubule-binding protein, is known to be highly
phosphorylated and degraded by the UPS (Dickey et al., 2006).
Therefore, we assessed the role of S5b/PSMD5 in tau phosphor-
ylation in S5b/PSMD5 Tg mice. Hyperphosphorylated tau
(p-Tau) increased in the cortex of S5b/PSMD5 Tg mice
compared to age-matched control littermates (Figure S7A).
Similarly, the level of p-Tau highly increased in cells over-
expressing S5b/PSMD5 or exposed to either TNF-a or MG132
(Figure S7B). These observations indicate that the increased
expression of S5b/PSMD5 enhances p-Tau accumulation in
cells and Tg mice.
Using the tauopathy fly model (gl-tau), which exhibits the
rough eye phenotype (Jackson et al., 2002), we further ad-
dressed the role of S5b/PSMD5 in the regulation of tau-mediated
neuronal degeneration. When the tau fly was crossed with the
S5b/PSMD5 mutant flies, the tau rough eye phenotype was
rescued in the CG12906f05782 fly and, to a lesser degree, in the
CG12906EY23373 fly (Figure 7D, bottom). In addition we crossed
the S5b/PSMD5mutant flies with the tau Tg fly, which expressed
tauR406W in the neurons, and compared their life spans. The
life span of S5b/PSMD5 mutant flies, CG12906f05782 and
CG12906EY23373, exhibited no apparent defects and were similar
to that of WT flies (average 43 days); the tau Tg fly exhibited
a shorter life span (average 33 days) (Figure 7F). When crossed
together, the life span of the tau Tg fly was significantly rescued
by S5b/PSMD5 deficiency (average 41 days in CG12906EY23373612 Cell Reports 2, 603–615, September 27, 2012 ª2012 The Authorand average 43 days in CG12906f05782). Thus, these observa-
tions indicate that S5b/PSMD5 deficiency in the flymodel neither
alters normal life span nor induces abnormal morphology but
suppresses neuronal toxicity of tau with enhanced proteasome
activity. We therefore propose that S5b/PSMD5 is a critical regu-
lator of proteasome activity in higher eukaryotic cells and animal
models and contributes to the pathogenesis of UPS-associated
neuronal disease, such as tauopathy.
DISCUSSION
S5b/PSMD5 Upregulated by TNF-a/NFkB
Is a Proteasome Inhibitor in Higher Eukaryotes
S5b/PSMD5 was initially isolated in two forms: acidic (S5a) and
basic (S5b) (Deveraux et al., 1995). Recently, yeast Hsm3 was
proposed as a homolog of human S5b/PSMD5 and as one of
the chaperones supporting 19S base assembly (Le Tallec
et al., 2009). From our genome-wide screening and subsequent
characterization, we found that excess S5b/PSMD5 inhibited
proteasome activity, probably via S7/PSMC2. S7/PSMC2 is
required for substrate unfolding and opening of the a ring
channel of CP (Murata et al., 2009).Mutation of S7/PSMC2 elicits
a severe growth defect in yeast (Rubin et al., 1998), and knock-
down of S7/PSMC2 expression in fly leads to incomplete 26S
proteasome assembly (Szabo´ et al., 2007). Likewise, downregu-
lation of S7/PSMC2 led to GFPu accumulation in mammalian
cells (Figure S2E). Given that the half-life of S7/PSMC2 is less
than 2 hr (Figures S5C and S5D), there is a possibility that the
S5b/PSMD5 in nonproteasome fractions inhibits proteasome
activity by binding to newly synthesized S7/PSMC2 and seques-
tering it into a nonproteasome complex, thereby causing a partial
deficiency of unstable S7/PSMC2 in 26S proteasome. The
release of S7/PSMC2 from S5b/PSMD5 in the nonproteasome
complex by the Tat-S5b peptide would rescue proteasome
activity.
In cells exposed to TNF-a, a small amount of S5b/PSMD5was
also detected in proteasome complexes (fractions 24–27) in
which the CP and RP subunits were detected. An inherent
function of S5b/PSMD5 may be to maintain the RP complex as
an assembly factor (Funakoshi et al., 2009; Park et al., 2009;
Saeki et al., 2009; Le Tallec et al., 2009). These observations
raise another possibility that excess S5b/PSMD5 may inhibit
the association of RP with CP by binding to the C terminus of
S7/PSMC2. This region of S7/PSMC2 is important for the
binding of RP to the a ring of CP (Smith et al., 2007; Le Tallec
et al., 2009). If so, the assembly of 26S complex could be de-
layed by the binding of excess S5b/PSMD5 to the RP complex
because assembly would only be completed once S5b/PSMD5
is dissociated from the complex. In addition, other possibilities,
such as S5b/PSMD5 modification by other proteins present in
the S5b/S7 complex, remain to be addressed.
In yeast, by contrast, Hsm3 deletion shows defective protea-
some function (Le Tallec et al., 2009). Although the function of
S5b/PSMD5 as a proteasome chaperone is well studied in yeast,
a study in mammalian cells did not show any obvious defects in
the proteasome assembly in S5b/PSMD5 knockdown cells
(Kaneko et al., 2009). Also, a recent report showed that Hsm3
overexpression inhibited proteasome assembly (Barrault et al.,s
2012). These observations raise a possibility that there may be
a functional difference in the role of S5b/PSMD5 in yeast and
higher eukaryotes, such as D. melanogaster and mouse, which
are functionally more complex than yeast (e.g., they have an
immune system). Furthermore, the sequence identity between
yeast Hsm3 and human S5b/PSMD5 is very low (less than
20%), whereas that of S7/PSMC2 is over 70% (http://www.ebi.
ac.uk/Tools/sequence.html, Needle program).
Rpn14 has been reported to act as a chaperone with Hsm3
during base assembly; its deletion causes a defect in base
assembly and inhibits 26S proteasome activity in yeast (Funa-
koshi et al., 2009; Park et al., 2009; Roelofs et al., 2009; Saeki
et al., 2009). In contrast, knockdown of PAAF1 (human homolog
of yeast Rpn14) expression in mammalian cells enhances pro-
teasome activity, and PAAF1 overexpression inhibits it (Lassot
et al., 2007; Park et al., 2005), whereas the effects were not as
big as S5b/PSMD5. In higher eukaryotes, S5b/PSMD5 and
PAAF1 may have distinct functions, though only the expression
of S5b/PSMD5 is regulated by TNF-a/NFkB. Thus, in addition
to their proposed inherent function in base assembly, levels of
the 19S proteasome assembly chaperones (e.g., S5b/PSMD5)
may also be an important determinant of proteasome activity.
Significance of Proteasome Inhibition by TNF-a/S5b/
PSMD5 in UPS-Associated Neuronal Degeneration
Reduced proteasome activity or increased inflammation has
been reported to decrease longevity and accelerate aging
(Hamer et al., 2010; Liu et al., 2011; Min et al., 2008). The S5b/
PSMD5 Tg mice were apparently smaller than age-matched
littermates, and their body weights were significantly decreased
with the premature onset of aging-associated phenotypes. On
the other hand, the UPS impairment hypothesis in neurodegen-
erative diseases remains controversial. In some studies, global
UPS impairment was not observed in HD model mice (Maynard
et al., 2009; Valera et al., 2007). Others observed that protea-
some inhibition caused the aggregation of misfolded proteins,
which was associated with perturbation of cellular functions
and various human disorders (Tyedmers et al., 2010). Our data
from tau protein support the latter that proteasome inhibition is
one of themajor factors involved in the pathogenesis of neurode-
generative diseases, depending on the nature of aggregation-
prone proteins. Therefore, UPS impairment is believed to be
associated with chronic neurodegenerative diseases (Ciechan-
over and Brundin, 2003).
Moreover, neuroinflammation is an important pathophysiolog-
ical feature of neurodegenerative diseases (Gao and Hong,
2008). Consistently, Tg mice expressing TNF-a in their brains
show chronic inflammation and neurodegeneration (Probert
et al., 1997). Thus, inhibition of the inflammation alleviates the
progression of neurodegenerative diseases (He et al., 2007;
Tweedie et al., 2007). Although many reports have suggested
that neuroinflammation mediates the pathology of neurodegen-
erative diseases, most studies havemainly focused on the role of
oxidative stress (Boje and Arora, 1992). On the other hand, we
propose that TNF-a inhibits proteasome activity/assembly in
higher eukaryotic cells. Thus, enhancement of proteasome
activity in neuronal cells and tissues can rescue tau-mediated
neuronal degeneration, as seen in our tau rough eye modelCelwith S5b/PSMD5 deficiency. Consistently, TNF-a potently in-
hibited proteasome activity via S5b/PSMD5 to increase the
number of mutant huntingtin exon1-containing expanded poly-
glutamine (n = 120) aggregates in neuronal cells (data not
shown). These findings suggest that in general, proteasome
inhibition resulting from upregulated S5b/PSMD5 may link the
neuroinflammation signal to neuronal degeneration in the afore-
mentioned diseases (e.g., AD and HD).
Unlike MG132 and in vitro analysis using purified S5b/PSMD5
protein and 26S proteasome, TNF-a and S5b/PSMD5 overex-
pression partially inhibited proteasome activity, ranging from
15% to 25% in cultured cells and 30%–40% in mouse tissues.
We believe that the relative ratio in the amount of S5b/PSMD5
protein to proteasome in cells under inflammation is not as
high as that in the in vitro analysis using purified proteins. In
addition, action mechanisms of MG132 and S5b/PSMD5 in the
proteasome inhibition are distinct. Given that most neurodegen-
erative diseases are chronic and associated with aging, the
partial inhibition of proteasome activity triggered by TNF-a,
IL-1b, or LPS may contribute to the pathogenesis of diseases
caused by chronic inflammation. We would like to define this
kind of proteasome regulation exhibited by S5b/PSMD5-
deficient flies and S5b/PSMD5 Tg mice as ‘‘chronic inhibition
of proteasome activity.’’ In conclusion we propose that S5b/
PSMD5 plays an important role in a tauopathy model and in
TNF-a/NFkB-mediated proteasome inhibition and has thera-
peutic potential in neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Cell-Based Functional Screening
HEK293T cells were grown in a 96-well culture plate for 24 hr and cotrans-
fected with GFPu and various cDNAs for 36 hr. Thereafter, cells were observed
under a fluorescence microscope, and relative fluorescence intensities were
compared to that of control (pcDNA). A monomeric RFP (mRFP), included in
every transfection, served as an internal transfection control. The cDNA
expression plasmids were constructed in pcDNA by PCR and analyzed by
DNA sequencing.
Cell Culture and DNA Transfection
HEK293T and other cells were obtained from the American Type Culture
Collection and grown in DMEM or RPMI containing 10% fetal bovine serum
and penicillin/streptomycin at 37C under 5% CO2 (v/v). NFkB p65
/ and
p50/MEFswere kindly provided by Dr. A. Hoffmann (University of California,
San Diego, La Jolla, CA, USA) (Hoffmann et al., 2003). Cells were transfected
with the appropriate vectors using Lipofectamine reagent (Invitrogen) accord-
ing to the manufacturer’s instructions.
Antibodies
The following antibodies were used: anti-S5b/PSMD5 (Novus); anti-S7/
PSMC2, anti-S4/PSMC1, anti-20S core antibodies (Biomol); anti-S2/PSMD2
antibody (Abcam); anti-GFP, anti-Tubulin, anti-Ub, anti-IkBa antibodies (Santa
Cruz Biotechnology); anti-p27/PSMD9, anti-p28/PSMD10, anti-PAAF1, anti-
TCF11/Nrf1 antibodies (Sigma-Aldrich); and anti-His antibody (Santa Cruz
Biotechnology). Anti-PHF-1 antibody was kindly provided by Dr. P. Davies
(Albert Einstein College of Medicine, Bronx, NY, USA).
Native-PAGE
Proteasome assembly was examined by native PAGE, as previously described
by Elsasser et al. (2005). Cell lysates were separated on 4% (w/v) native-PAGE
at 4C. The gel was overlaid with buffer containing Suc-LLVY-AMC with orl Reports 2, 603–615, September 27, 2012 ª2012 The Authors 613
without 0.001% SDS, or transferred to nitrocellulose membranes for western
blot analysis.
Preparation of Cell Extracts and Separation of Proteasome
Complexes by Gel Filtration
Cells were lysed in a lysis buffer (20 mM Tris-HCl [pH 7.5], 100 mM NaCl,
0.1 mM EDTA, 2 mM ATP), lysates were centrifuged at 12,000 rpm for
30 min at 4C, and the supernatant was filtered through a 0.2 mm membrane
(Sartorius). Gel filtration was carried out using a Superose 6 FPLC column
(AKTA; GE Healthcare), and 0.25 ml fractions were collected.
Proteasome Activity Assays
After preparation of cell lysates in retic buffer, proteasome activities were
measured using the fluorogenic substrates Suc-LLVY-AMC, Bz-VGR-AMC,
and Ac-GPLD-AMC (Biomol) and a fluorometer (FlexStation 3 Microplate
Reader; Molecular Devices). The excitation and emission wavelengths were
380 and 460 nm, respectively. Purified 26S proteasome was purchased from
Boston Biochem.
In Vitro Ubiquitination
HEK293T cell lysates (100 mg) were incubated with purified His-S5b/PSMD5
(3 mg) at 37C in ubiquitination buffer (10 mM Tris [pH 7.4], 150 mM NaCl,
3 mM MgCl2, 1 mM EDTA, 0.5 mM PMSF, 1 mM DTT, 10% glycerol, 1 mM
ATP, 13 ATP regeneration system, 13 protease inhibitor cocktail). Cell lysates
were then subjected to SDS-PAGE for western blotting or assayed for protea-
some activity using Suc-LLVY-AMC.
Preparation of Tat-S5b Peptide
S5b/PSMD5 (181–188) (VRYRVYEL) and S5b/PSMD5 R184E (VRYEVYEL)
peptides were synthesized and coupled to amembrane-permeant Tat-derived
sequence (YARAAARQARA) (Peptron, Daejeon, South Korea).
Tauopathy Flies
D. melanogaster was raised in the dark at 25C. The WT (W1118) and S5b/
PSMD5mutant (CG12906f05782 andCG12906EY23373) strains used in this study
were obtained from the Bloomington Drosophila Stock Center at Indiana
University. Various genetic combinations were generated using standard
crosses.
Generation of Tg Mouse
The pCAGGS-HA-S5b/PSMD5 vector was injected into mouse embryos with
a C57BL genetic background, and three independent founders (F0) were iden-
tified by PCR analysis using synthetic oligonucleotides (forward, TG S5b-F;
reverse, S5b N1-R) (Macrogen, Seoul, Korea). The primer sequences are listed
in Table S2.
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